Search Results
Your search for ASCO matches 21361 pages
Showing 20951 - 21000Genetic Anti-Inflammatory Defect May Predispose Children to Lymphoma
New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, reveal an important association between the genetic defect, which causes chronic intestinal...
ASCO Releases Statement on the Impact of the Government Shutdown on Cancer Care
All nonessential government services were suspended at midnight after Congress failed to reach a budget compromise to keep the government funded before the start of the new fiscal year beginning on October 1, 2013. ASCO issued a statement today in response to the government shutdown and will be...
Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...
ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer
Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...
Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
FDA Approves Neoadjuvant Pertuzumab for Early-Stage Breast Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel for patients with early-stage breast cancer in the neoadjuvant setting. Pertuzumab is the first FDA-approved drug for the neoadjuvant...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...
ASTRO: Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Memory Loss in Cancer Patients
Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...
ASTRO: Intensity Modulated Proton Therapy May Preserve Quality of Life in Patients With Oropharyngeal Cancer
A new study from researchers at The University of Texas MD Anderson Proton Therapy Center found that the use of feeding tubes in patients with oropharyngeal cancer treated with intensity modulated proton therapy decreased by more than 50% compared to patients treated with intensity modulated...
Large Retrospective Study Finds Association Between Marriage and Cancer Outcomes
New results from a large retrospective study of the National Cancer Institute’s SEER database, published in the Journal of Clinical Oncology, show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
USPSTF Issues Final Recommendation Statement on Medications for the Risk Reduction of Primary Breast Cancer in Women
The U.S. Preventive Services Task Force (USPSTF) released today its final recommendation statement on medications to reduce the risk of primary breast cancer in women. Clinicians are recommended to prescribe risk-reducing medications, such as tamoxifen or raloxifene, for women who are at increased...
ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Researchers Uncover Root Cause of Multiple Myeloma Relapse
Researchers have discovered why multiple myeloma frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. The study, published in Cancer Cell, was a collaboration between researchers at Princess Margaret Hospital in Toronto, Mayo Clinic in...
Scientists Find Possible Antidote for Tamoxifen-Induced Mental Fog
Researchers from University of Rochester Medical Center have shown scientifically what many women report anecdotally: that tamoxifen is toxic to cells of the brain and central nervous system (CNS), producing mental fogginess similar to “chemo brain.” In the study, published in the...
Statement by ASCO President Clifford A. Hudis, MD, FACP, in Support of the Rally for Medical Research Hill Day
“With the unprecedented scientific opportunities now promising significant progress against cancer and other life-threatening diseases, it is a tragedy that we are even considering cuts to our nation's investment in biomedical research. Yet, such cuts are already happening because of the...
MicroRNA Molecule Found to Be a Potent Tumor Suppressor in Lung Cancer
New research shows that microRNA-486 (miR-486) is a potent tumor-suppressor molecule in lung cancer, and that it helps regulate the proliferation and migration of lung cancer cells, as well as the induction of apoptosis in those cells. Published in the Proceedings of the National Academy of...
Young Breast Cancer Patients May Overestimate Benefit of Contralateral Prophylactic Mastectomy
Young women with breast cancer may overestimate the risk that cancer will occur in their other healthy breast and decide to undergo contralateral prophylactic mastectomy, a survey conducted by Dana-Farber Cancer Institute investigators indicated. The survey also shows that many patients may opt for ...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
New Medical Device Treats Urinary Symptoms Related to Benign Prostatic Hyperplasia
The U.S. Food and Drug Administration has authorized the marketing of the UroLift system, a permanent implant to relieve low or blocked urine flow in men age 50 and older with benign prostatic hyperplasia. As men age, the prostate can become enlarged, also known as benign prostatic hyperplasia....
FDA Grants Priority Review Designation for Dabrafenib/Trametinib Combination in Metastatic Melanoma
GlaxoSmithKline recently announced that the U.S. Food and Drug Administration has granted Priority Review designation to its supplemental New Drug Applications for the combined use of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of adult patients with unresectable or metastatic ...
FDA Grants Volasertib Breakthrough Therapy Designation in Acute Myeloid Leukemia
Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...
FDA Approves First Generic Capecitabine to Treat Colorectal and Breast Cancers
The U.S. Food and Drug Administration (FDA) has approved the first generic version of capecitabine (Xeloda), an oral chemotherapy agent used in the treatment of metastatic colorectal cancer and breast cancers. Teva Pharmaceuticals USA has gained FDA approval to market generic capecitabine in 150...
FDA Grants Ofatumumab Breakthrough Therapy Designation for Previously Untreated CLL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ofatumumab (Arzerra) in combination with chlorambucil (Leukeran) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment and are inappropriate for...
Gene Expression–Based Biomarker Predicts Long-Term Risk of Breast Cancer Recurrence
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor–positive breast cancer found that only the breast cancer index (BCI)—a biomarker based on the expression levels of seven tumor-specific genes—accurately identified patients...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
ODAC Recommends Accelerated Approval of Pertuzumab for HER2-Positive, Early-Stage Breast Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a pertuzumab (Perjeta) regimen for neoadjuvant treatment in patients with high-risk, HER2-positive, early-stage breast...
Brachytherapy to Treat Cervical Cancer on the Decline in the United States
A study by researchers at Brigham and Women's Hospital found that brachytherapy was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis also revealed geographic disparities and decline in brachytherapy treatment in the...
Dana-Farber Mourns the Passing of Jane Carrie Weeks, MD, MSc, National Leader in Outcomes Research
Jane Carrie Weeks, MD, MSc, a prominent researcher at Dana-Farber Cancer Institute, internationally known for building the discipline of outcomes research in oncology and admired by colleagues as an outstanding mentor, died September 10 after a long illness. She was "one of the true intellectual...
ASCO Issues Statement on National Childhood Obesity Awareness Month
Today, as many as 23 million children and teens are obese or overweight, and it is estimated that more than one-third of U.S. adults (more than 72 million people) are obese, according to a statement released by ASCO to help raise awareness of National Childhood Obesity Awareness Month....
Versatile MicroRNAs Block Cancer Blood Supply, Suppress Metastasis
A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center reported in Nature Communications. Patients with lung, ovarian, kidney, or...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
FDA Grants Breakthrough Therapy Status to Entinostat for Advanced Breast Cancer
Syndax Pharmaceuticals Inc today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor (ER)-positive breast cancer when added to exemestane in postmenopausal women whose...
FDA Announces Class-Wide Safety Labeling Changes for Long-Acting Opioid Analgesics to Combat Abuse
The U.S. Food and Drug Administration (FDA) today announced class-wide safety labeling changes and new postmarketing study requirements for all extended-release and long-acting opioid analgesics intended to treat pain. “The FDA is invoking its authority to require safety labeling changes and ...
Researchers Uncover Genetic Cause of Childhood Acute Lymphoblastic Leukemia
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery was reported...
Dr. Larry Norton, Honored at 2013 Breast Cancer Symposium, Calls for Return to the ‘Exploration of Concepts’
Larry Norton, MD, of Memorial Sloan-Kettering Cancer Center, is the recipient of the 2013 Gianni Bonadonna Breast Cancer Award, which he received at the 2013 Breast Cancer Symposium. The Symposium is sponsored by ASCO, the American Society of Breast Surgeons, the American Society of Radiation...
Majority of Breast Cancer Deaths Occur in Younger, Unscreened Women, Study Finds
A new analysis has found that most deaths from breast cancer occur in younger women who do not receive regular mammograms. Published early online in Cancer, the study indicates that regular screening before age 50 should be encouraged. The use of mammograms to prevent breast cancer deaths has been ...
Molecular Marker Predicts Patients Most Likely to Benefit Longest From EGFR Inhibitors
Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...
FDA Approves Nab-Paclitaxel for Late-Stage Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) today expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abraxane) to treat patients with late-stage pancreatic cancer. “Patients with pancreatic cancer are often diagnosed...
New Laser-Based Tool Could Dramatically Improve the Accuracy of Brain Tumor Surgery
A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor. In a new paper published in Science Translational...
Swallowing Exercises Preserve Function in Patients Receiving Radiation for Head and Neck Cancer
A study from UCLA's Jonsson Comprehensive Cancer Center (JCCC) has found that patients with head and neck cancer receiving radiation as part of their treatment were less likely to suffer unwanted side effects such as worsening of diet, need for a feeding tube, or narrowing of the throat passage if...
MRI Around the Time of Surgery Does Not Reduce Recurrence Rates in Women With DCIS
A large retrospective study reported that adding magnetic resonance imaging (MRI) to mammography before or immediately after surgery was not associated with reduced local recurrence or contralateral breast cancer rates among women with ductal carcinoma in situ (DCIS) of the breast who were treated...
Large Study Shows That Radiation Therapy for DCIS May Not Increase Cardiovascular Disease Risk
A large population-based study in the Netherlands found that women who had received radiation therapy to treat ductal carcinoma in situ of the breast (DCIS) have no increased risk of cardiovascular disease compared to the general population of Dutch women, nor compared to DCIS patients treated with ...
Most Women Have an Inaccurate Perception of Their Breast Cancer Risk, Study Reveals
A large-scale survey of women undergoing mammography screening on Long Island, New York, indicates that the majority (90.6%) either underestimate or overestimate their lifetime risk for developing breast cancer. Furthermore, 4 in 10 women surveyed reported they had never discussed their...
New Report Examines Trends in End-of-Life Care for Patients With Advanced Cancer
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project. The findings also show that a significant number of patients were likely to...
